Credit Suisse’s DICE Therapeutics DICE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-69,258
Closed -$3.22M – 3207
2023
Q2
$3.22M Buy
69,258
+42,855
+162% +$1.48M ﹤0.01% 1622
2023
Q1
$756K Buy
26,403
+8
+0% +$237 ﹤0.01% 2490
2022
Q4
$824K Buy
26,395
+17,399
+193% +$567K ﹤0.01% 2472
2022
Q3
$181K Buy
8,996
+139
+2% +$2.53K ﹤0.01% 3283
2022
Q2
$138K Buy
+8,857
New +$152K ﹤0.01% 3453

Credit Suisse's DICE Position: Q3 2023 in Review

Credit Suisse sold out of DICE Therapeutics (DICE) in Q3 2023, closing a stake of 69,258 shares — an estimated $3.22M sold.

Credit Suisse first reported a position in DICE in Q2 2022 and held it in 5 quarters. The position peaked at $3.22M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • Credit Suisse reported no remaining DICE Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Credit Suisse sold 69,258 DICE Therapeutics shares in Q3 2023, an estimated $3.22M.
  • Credit Suisse first reported a position in DICE Therapeutics in Q2 2022 and held it in 5 quarters.
  • Credit Suisse's DICE Therapeutics position peaked at $3.22M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics as of Q3 2023.

Based on Credit Suisse's 13F filing for Q3 2023, filed 13 Nov 2023.